endo Flashcards
what drugs increase the risk of gout
thiazide diuretics
cyclosporines +tacrolimus
allopurinol + probenecid *initial increase in risk of acute gout attacks)
describe the HPA axis for prolactin
what effect do mental/emotional and physical stress have on blood glucose levels
physical stress (i.e. excercise) –> hypo-glycemia
mental/emotional stress –> hyper-glycemia
general symptoms seen in glycogen storage disorders vs lysosomal storage disorders
(list the big examples of each)
GLYCOGEN STORAGE DS
- hypoglycemia, change in blood lactate levels, change in skeletal M tone, myoglobinurea
- secondary effects on cardiac myscle
- GLYCOGEN ACCUMULATIONS WILL STAIN PAS+
- 1= von gierke : 2=pompe : 3= cori : 4=mcardle
LYSOSOMAL STORAGE DS
- neurodegeneration/demyelination, angiomatosis-like processes, changes in marrow EPO
- secondary effects on liver+spleen (extramedullary hematopoeisis)
- SPHINGLIPIDOSES (tay-sachs, niemann pick, gaucher, fabry, kravve, metachromatic leukodystrophy) + MUCOPOLYSACCHARIDOSES (Hurler+Hunter)
who are the three regulators of glycogen levels in the body and how do they exert their effect
glycogen is stored in the liver and in skeletal M
-
glucagon + epinephrine –> stimulate glycogen phosphorylase kinase –> phosphorylate glycogen phosphorylase –> breakdown of glycogen into glucose
- glucagon: liver glucagon receptors = Gs-linked –> cAMP–> PKA–> inc GPK
- epinephrine: liver+M (beta)R = Gs-linked –> cAMP–> PKA–> inc GPK
- epinephrine: liver alpha-R = inc Ca release from ER –> inc GPK
- insulin –> stimulate glycogen synthase –> build glucose into glycogen
- TRK dimerization on liver –> inc protein phosphotase –> inc GS
where in the body do these occur?
- glycogenesis
- glycogenolysis
who are the big enzymes in these processes
which diseases are associated with each?
liver and sk. M >> adipose - CYTOPLASM
GLYCOGENESIS: glucose –> glycogen
- glucose –> G6P –> G1P…
- G1P –> UDP glucose = UDP-glucose pyrophosphorylase
- UDP-glucose –> glycogen = glycogen synthase
- add a branch to glycogen = branching enzymes
GLYCOGENOLYSIS: glycogen –> glucose
- first step= RATE LIMITING STEP = glycogen phoshphorylase will take G1Ps off the end of a branch until there are just 4 G1Ps left on the branch
- x (in M cells only) = McArdle Ds
- OR lysosomal alpha-1,4 glucosidase can break down branched glycogen into glucose directly
- x= Pompe Ds
- debranching enzymes : x= Cori Ds
- will relocate the 3 G1Ps at the end of the branch to the end of the main stem =4-alpha-D glucanotransferase
- debranch the last G1P = alpha 1,6 glucosidase
- once debranched, removed each G1P at a time –>
- G1P –> G6P –> glucose
- G6P –> glucose = glucose 6 phosphatase x = Von Gierke Ds
- G1P –> G6P –> glucose
McArdle Ds, Cori Ds, Pompe Ds, Von Gierke Ds
- x enzyme –> what builds up, what cannot be made
- clin features
- blood glucose levels
- other key lab findings
McArdle Ds <em>McArdle McMuscle Man</em>
- x enzyme
- x glycogen phosphorylase IN THE SKELETAL M, enzyme intact in the liver
- build up of muscle glycogen, but defiency of glucose in the skeletal M
- clin features
- only have M sx = M cramps and myoglobinuria after intense excercise / high glucose demand on Muscles that can’t be met
- pain with excercise
- blood glucose levels
- normal
- other key lab findings
- inc CK, urine is red but MYOglobin= no RBCs in urine, inc M BF in an attempt to provide more nutrients and glucose
- electrolyte abnormalities –> arrythmias
- no lactic acid production during excercise, normal ammonium production
CORI DS *Cori Coral Branches on Mild Beaches*
- x enzyme
- = debranching enzymes: α-1,6-glucosidase and 4-α-d-glucanotransferase
- clin features
- mild hypoglycemia, mild inc TG
- gout, liver and renal inc size
- cardiomyopathy
- blood glucose levels
- mild hypoglycemia
- other key lab findings
- normal blood lactate
- NORMAL gluconeogenesis (pyruvate–>glucose), impaired glycogenolysis (glycogen–>glucose)
POMPE DSAbn Cell-Volcano (lysosome) –> systemic destruction, death
- x enzyme
- x lysosomal acid α-1,4- glucosidase (acid maltase) (cannot break linked G1Ps)
- n lysosomal acid α-1,6- glucosidase
- clin features
- hypotonia, proximal M wknss+dystrophy, resp M wknss
- excercise intolerance
- cardiomegaly+hypertrophic cardiomyopathy
- early systemic findings + death
- blood glucose levels
- normal
- other key lab findings
- x heart, liver, and muscle activity
VON GIERKE DS
- x enzyme
- x glucose-6-phosphatase
- build up of G6P, glucose deficiency
- clin features
- SEVERE FASTING hypoglycemia,
- inc uric acid –> inc GOUT
- hepatomegaly, renomegaly
- blood glucose levels
- severely low
- other key lab findings
- inc TGs
- INC BLOOD LACTATE (vs Cori)
- inc glycogen build up in liver and kidneys
- x glycogenlysis AND gluconeogenesis –> require frequent oral glucose intake
- AVOID FRUCTOSE AND GALACTOSE (bc cannot make glucose)
ketoacidosis develops from the lack of insulin due to what function of insulin failiing to be carried out
inhibition of lipolysis and ketogenesis
tingling and M cramps results from ____calcemia
HYPOcalcemia i..e chvostek’s sign
at what step does insulin affect glycolysis
insulin –> inc phosphofructokinase-2 (PFK2)
fructose 6-phosphate –> fructose1,6 bisphosphate
=inc glycolysis
what pathways induce releases insulin from the pancreatic beta cells
GLUCOSE-GLUT2
- glucose enters the beta cells through GLUT-2
- glucose–glucokinase–> glucose-6-phosphate
- G6P enters glycolysis, produces ATP
- inc ATP –> closure of ATP-sensitive K channels on the beta cell membrane –> stop outflow of K+ –>depolarize beta cells
- depolarization of beta cells triggers opening of voltage-dependent Ca channels on membrane –> inc Ca influx into beta cells
- inc Ca levels –> insulin release
GLP-1
- glucagon-like peptide 1 binds to GLP-1 receptor on beta cells
- inc intracellular cAMP
- insulin release
embryologic malfunction in digeorge syndrome that leads to hypocalcemia?
failure of neural crest migration into the third and fourth pharyngeal pouches
- x third pouch –> x inferior parathyroid+ thymus
- x fourth pouch –> x superior parathyroid
how do defects in fructose metabolism present
- etiology +pathophys
- clin
- trx
essential fructosuria =
- x fructokinase = x fructose–>fructose-1P
- benign, fructosuria because of compensatory hexokinase activity (converts fructose–>F6P so it can enter glycolysis)
hereditary fructose intolerance =
- AR x adolase B = x fructose1P–> DHAP –>GAP-3P (enter gluconeogenesis
- build-up of toxic fructose 1P–> depletion of intracellular phosphate + inhibition of gluconeogenesis
- present with severe, lifethreatening hypoglycemia when baby starts to consume formula or real food
- not only are they not breaking down fructose, but they are not producing glucose from gluconeogenesis
- hypoglycemia –> pale, diaphoretic, lethargy, V/D
- trx = stop intake of fructose, sucrose (fructose+sucrose), and sorbitol (metabolized into fructose)
what four functions will pyruvate go on to play in the body and what cofactors are needed for each function
what essential substances are derived from the following amino acids
- phenylalanine
- tyrosine
- tryptophan
- histidine
- glycine
- glutamate
- arginine
how deficiencies in the enzymes needed for glycolysis typically present?
what are the important enzymes in this pathway?
hemolytic anemia –> without glycolysis, RBCs will die
in what 3 ways can a 21-alpha hydroxylase deficiency present
what changes will be seen in the adrenal gland
=adrenal cortex hyperplasia
what is the clinical indication for thiazolidinediones and what is their mechanism of action
thiazolidinediones
=class of drugs use to treat insulin resistance
- bind to PPAR-y (peroxisome-proliferator-activated receptor gamma) in the nucleus
- PPAR-y is a nuclear receptor and transcription factor that will bring RXR when activated by the TZD
- PPARy-TZD binding to DNA will result in
- inc FA uptake and adiponectin production, dec leptin production
- inc insulin sensitvity in liver and M
- dec TNF-alpha production
what is the pathway that leads to creation of ketone bodies
hormone sensitive lipase is activated by: stress hormones (ACTH, catecholamines, glucaon)
which endocrine hormones are NOT lipophilic and must bind surface
- G protein coupled receptors
- tyrosine kinase receptors
- G protein coupled receptors
- ACTH, ADH, epinephrine, glucagon
- tyrosine kinase receptors
- insulin, growth hormone
what is the clinicial indication for and MOA of dipeptidyl peptidase-4 inhibitors
improves glycemic control and decreases hgbA1C
how does congenital hypothyroidism present
as maternal T4 wanes (a couple months): baby becomes difficult to rouse from naps + lethargic
–>puffy face and irreversible intellectual disability
-trx with levothyroxine starting at 2 weeks can prevent the development of sx
phenylalanine metabolism requires what cofactors
dihydrobiopterin reductase
list the 6 big lysosomal storage diseases
- x enzyme, inheritance
- accumulation of what
- clinical features
- special lab/test/histo findings
Tay Sachs Ds
- x AR hexosaminidase A heXosaminidase x in taysaX(1)
- accumulate GM2 ganglioside
- neurodegeneration+developmental delay, hyperreflexia,
- cherry red spot on macula, onion skinning of lysosomes
Niemman-Pick Ds
- x AR sphingomyelinase (6)
- accumulation of sphingomyelin,
- progressive neurodegeneration, hepatomegaly (in contrast to taysachs)
- cherry red spot on macula, foam cells (lipid laden macrophages)
gaucher ds
- x AR glucocerebrosidase (5)
- inc glucocerebroside
- MC OF ALL DSs: hepatosplenomegaly, pancytopenia, osteoporosis, avascular necrosis of the femur
- Gaucher cells= lipid laden macrophages that looked like crumpled up tissue paper
Fabry ds
- XR x alpha galactosidase A (2)
- inc ceramide trihexodase
- early= TRIAD : episodic peripheral neuropathy + angiokeratomas (small dark spots on the skin) + hypohidrosis (dec sweating)
- late= progressive renal failure + CV ds
Krabbe ds
- AR x galactocerebrosidase (4)
- inc galactocereroside
- peripheral neuropathy, destroyed oligodendrocytes, developmental delay
- optic atrophy, globoid cells (giant multinucleated cells)
metachromatic leukodystrophy
- AR xarylsulfatase
- cerebroside sulfate
- central and peripheral demyelination w ataxia+dementia
what is the mechanism of action of glyburide
what other medication is in the same class as this drug
glyburide = a sulfonylnurea second generation
- close ATP-sensitive K-channels on pancreatic beta cell membrane –> inc intracellular Ca –> release insulin INDEPENDENT OF GLUCOSE LEVELS
glipizide + glyburide = 2nd gen sulfonylurea
what are the 4 big MOAs of DM drugs
what are the drug classes
- inc insulin sensitivity
- metformin : inhibit mGPD–> x hepatic gluconeogenesis , inc glycolysis and peripheral glucose uptake
- glitazones (aka thiazolidinediones) : activate PPAR-y = regulate glucose metabolism and fatty acid storage
- inc insulin secretion (glucose independent)
- sulfonylurea (1st gen= chlorpropamide, tolbutamide) (2nd gen= glipizide, glyburide), meglinitides (“-glinide”) = close K+ channels–> release insulin via inc Ca
- inc glucose induced insulin secretion
- GLP-1 analogs= exenatide, liraglutide –> dec glucagon release and gastric emptyinh, inc insulin release w glucose
- DPP-4 inhibitors (-glips) –> inhibit the GLP-1 inhibitors, so increase the actions of GLP-1
- decrease glucose absorption
- Na-glucose cotransporter 2 (SGLT2) inhibitors “-gliflozin” –> block reabsorp of glucose in PCT
- alpha-glucosidase inhibitors (acarbose, miglitol) –> inhibit intestinal brush border alpha glucosidase –> dec prostprandial hyperglycemia
what type of insulin is prescribed for
- once daily use
- twice daily use
- post-prandial use
- IV use for DKA
- once daily use
- basal long acting: glargine, detemir, degludec
- twice daily use
- basal intermdiate acting: NPH (isophane)
- post-prandial use
- short acting (peak 0.5-3 hrs): lispro, aspart, glulisine
- IV use for DKA
- short acting, regular insulin: peak 2-5 hours
what process is disrupted by anti-TPO enzymes
thyroglobulin iodinization
how do the following affect the pathway that leads to Vit D synthesis
- sunlinght
- PTH
- Ca
7-dehydrocholesterol –UV LIGHT–> cholecalciferol –> 25 hydroxy-VitD
PTH and Ca work on 25VitD –1-alpha-hydroxylase–> 1,25 VitD in the liver
PTH= inc, Ca= dec
in general, patient’s with DM are most likely to die from what
coronary heart ds (MI)
what are the endocrine effects of a prolactinoma
describe the mechanism by which CKD can lead to changes in serum Ca and bone density
CKD –> dec 1,25VitD production
- –> dec Ca reabsorption from small intestine
- –> secondary inc in PTH = secondary hyperparathyroidism
- –> inc osteoclast activity = renal osteodystrophy
which class of anti-hyperlipidemics is most effective at
- dec LDLs
- dec TGs
- inc HDLs
- dec LDLs
- statins
- dec TGs
- fibrates
- inc HDLs
- niacin
does oral glucose or IV glucose have a greater effect on insulin release into the body
why
oral glucose : bc will stimulate incretins which will further inc insulin release
- GLP-1
- gastric inhibitory protein (GIP)
which substance will provide feedback to determine whether pyruvate will enter the TCA cycle or gluconeogenesis
what enzymes are involved?
what changes are seen in the pancreas in DM type 1 vs type 2
Type 1 DM = islet infiltration with leukocytes (associated with HLA and anti-islet Abs)
Type 2 DM= amyloid deposition